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Background: In the Western world, dietary supplements are commonly used to prevent chronic diseases, mainly
cardiovascular disease and cancer. However, there is inconsistent evidence on which dietary supplements actually
lower risk of chronic disease, and some may even increase risk. We aim to evaluate the comparative safety and/or
effectiveness of dietary supplements for the prevention of mortality (all-cause, cardiovascular, and cancer) and
cardiovascular and cancer incidence in primary prevention trials.
Methods/Design: We will search PubMed, EMBASE, Cochrane Database of Systematic Reviews, the Database of
Abstracts of Reviews of Effects, the Cochrane Central Register of Controlled Trials, clinical trials.gov, and the World
Health Organization International Trial Registry Platform. Randomized controlled trials will be included if they meet
the following criteria: (1) minimum intervention period of 12 months; (2) primary prevention of chronic disease
(is concerned with preventing the onset of diseases and conditions); (3) minimum mean age ≥18 years
(maximum mean age 70 years); (4) intervention(s) include vitamins (beta-carotene, vitamin A, B vitamins, Vitamin
C, Vitamin D, Vitamin E, and multivitamin supplements); fatty acids (omega-3 fatty acids, omega-6 fatty acids,
monounsaturated fat); minerals (magnesium, calcium, selenium, potassium, iron, zinc, copper, iodine; multiminerals);
supplements containing combinations of both vitamins and minerals; protein (amino acids); fiber; prebiotics; probiotics;
synbiotics; (5) supplements are orally administered as liquids, pills, capsules, tablets, drops, ampoules, or powder;
(6) report results on all-cause mortality (primary outcome) and/or mortality from cardiovascular disease or cancer,
cardiovascular and/or cancer incidence (secondary outcomes).
Pooled effects across studies will be calculated using Bayesian random effects network meta-analysis. Sensitivity
analysis will be performed for trials lasting ≥5 years, trials with low risk of bias, trials in elderly people (≥65 years),
ethnicity, geographical region, and trials in men and women. The results of the corresponding fixed effects
models will also be compared in sensitivity analyses.
Discussion: This is a presentation of the study protocol only. Results and conclusions are pending completion of this
study. Our systematic review will be of great value to consumers of supplements, healthcare providers, and policy-makers,
regarding the use of dietary supplements.
Systematic review registration: PROSPERO: CRD42014014801.
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The use of dietary supplements has increased over time in
the United States. In the National Health and Nutrition
Examination Survey I, the prevalence of dietary supple-
ment use was 28% among males and 38% among females.
The most recent data indicate that about one-half of the
U.S. population and 70% of adults ≥71 years of age use
dietary supplements. The most predominant supplements
are multivitamin-multi-mineral supplements, which ac-
count for about one third [1]. Magnesium was the most
used mineral dietary supplement [1]. High quality data for
comparisons among European countries are sparse [2]. The
largest European cohort study until to date, the European
Prospective Investigation into Cancer and Nutrition study,
indicates that there are significant differences in dietary
supplement intake in Europe, varying between 2% in Greek
men and 66% in Danish women [3]. Overall dietary sup-
plement use was more prevalent in Northern European
countries compared to southern countries, especially
higher intakes of cod liver oil could be observed [3].
There is evidence that specific populations such as
cancer survivors have a higher intake of dietary supple-
ments, compared to the general healthy population [4,5].
Previous pairwise meta-analyses of randomized con-
trolled trials showed inconsistent effects of dietary sup-
plements [6,7]. One of the largest meta-analysis showed
that treatment with beta-carotene, vitamin A, and vita-
min E may increase mortality [8], whereas vitamin D
supplementation seems to be associated with reduced
mortality [9,10]. Vitamin B supplementation has a sig-
nificant protective effect on stroke, but no effect on
CVD mortality or cancer [11,12], whereas calcium sup-
plementation has no significant effects on cancer risk
[13]. Omega-3 fatty acids are probably the most studied
dietary supplements, and recent meta-analyses showed
no protective effects on cardiovascular disease [14,15].
However, there seems to be some differences between
primary and secondary prevention trials, between lower
vs. higher dose of omega-3 fatty acids, and between dif-
ferent clinical endpoints [16,17].
To date, no systematic review and meta-analysis has
jointly synthesized the direct and indirect evidence of
the effects of all dietary supplements on all-cause
mortality, cardiovascular mortality, cancer mortality,
incidence of CVD, and cancer. Therefore, we aim to
summarize all the available evidence on dietary sup-
plements and mortality (all-cause, cardiovascular, can-
cer) and incidence (cardiovascular disease, cancer) as
well as to assess the efficacy and safety of different
dietary supplements in primary prevention trials.
Methods/Design
The review was registered in PROSPERO International Pro-
spective Register of Systematic Reviews (www.crd.york.ac.uk/prospero/index.asp, identifier CRD42014014801). The
present systematic review protocol was planned, conducted,
and reported in adherence to standards of quality for
reporting systematic review and meta-analysis protocols
(PRISMA-P) [18,19].
Eligibility criteria
Studies will be included in the meta-analysis if they meet
all of the following criteria:
(1) Randomized controlled design (identical placebo or
no intervention) or trials of one supplement vs.
another;
(2) Minimum intervention period of 12 months;
(3) Primary prevention (of chronic disease) trials (trials
concerned with preventing the onset of diseases and
conditions);
(4) Minimum mean age ≥18 years;
(5) Intervention: dietary supplements defined according
to the Directive 2002/46/EC of the European
parliament and of the Council, of 10 June 2002 [20];
the following dietary supplements will be included
(according to previous systematic reviews and
meta-analyses on dietary supplements and chronic
diseases [8,10,15]); vitamins (beta-carotene, Vitamin
A, B vitamins (thiamin, riboflavin, niacin, pyridoxine,
cobalamin, folic acid), Vitamin C (ascorbic acid),
Vitamin D (cholecalciferol, ergocalciferol, alfacalcidol,
calcitriol), Vitamin E, and multivitamin supplements)
supplements containing a combination of different
vitamins; fatty acids: omega-3 fatty acids
(eicosapentaenoic acid, docosahexaenoic acid,
α-linolenic acid); omega-6 fatty acids (linoleic
acid); monounsaturated fat (olive oil); minerals:
magnesium, calcium, selenium, potassium, iron, zinc,
copper, iodine; multi-minerals; and supplements
containing combinations of both vitamins and
minerals; protein (amino acids: alanine, arginine,
asparagine, aspartic acid, cysteine, glutamic acid,
glutamine, glycine, proline, selenocysteine, serine,
tyrosine, isoleucine, leucine, lysine, methionine,
phenylalanine, threonine, tryptophan, valine); fiber
(psyllium, inulin, cellulose); probiotics (‘viable
microorganisms, sufficient amounts of which reach
the intestine in an active state and thus exert positive
health effects’: Lactobacillus rhamnosus GG,
Lactobacillus reuteri, bifidobacteria and certain
strains of Lactobacillus casei or the Lactobacillus
acidophilus-group, Escherichia coli strain Nissle 1917,
certain enterococci (Enterococcus faecium SF68) and
the probiotic yeast Saccharomyces boulardii); prebiotics
(‘a selectively fermented ingredient that allows specific
changes, both in the composition and/or activity in the
gastrointestinal microflora that confers benefits upon
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galactooligosaccharides); synbiotics (‘synergistic
combinations of pro- and prebiotics’) [21];
(6) Oral intake: modalities of supplement intake: liquid,
pill, capsule, tablet, drops, ampoule, powdered;
(7) Assessment of the ‘primary’ outcomes: all-cause
mortality, ‘secondary’ outcomes: cardiovascular
mortality, cancer mortality; cardiovascular incidence,
and cancer incidence (trials must report at least one
of these outcomes).
(8) Report the number of events, sample size, and
follow-up time for each group, or report the hazard
ratio with a measure of uncertainty or where there
are sufficient details for this to be calculated (for
example, from a confidence interval or P value).
Exclusion criteria
(1) Exclusion of studies with a dietary co-intervention
that was not applied in all the intervention or pla-
cebo/control groups;
(2) Exclusion of studies with a drug-intervention that
was not applied in all the intervention or placebo/
control groups (that is, trials allowing concomitant
medications will be included if applied in all groups
in a comparable regimen);
(3) Studies with intravenous or parenteral administration
of vitamins or minerals will be excluded;
(4) Pregnant or lactating women will be excluded.
(5) Mean age ≥70 years;
(6) Non-primary prevention trials (>75% of sample
size) will be excluded (defined as trials undertaken
to prevent recurrences or exacerbations of a disease
that has already been diagnosed: cancer survivors,
survivor of myocardial infarction, stable/unstable
angina pectoris, acute coronary insufficiency,
coronary artery disease (verified by coronary
angiography), stroke, hemodialysis, chronic kidney
disease, and subjects with the following diseases:
gastrointestinal, neurological, ocular, dermatological,
rheumatoid, endocrinological).
(7) Follow-up time is not reported.
Study type
Only RCTs that are peer-reviewed and available in full-
text are eligible for the present network meta-analysis.
The following type of studies will be excluded: observa-
tional studies, case series, and case reports.
Search strategy
We will conduct searches in Cochrane Central Register
of Controlled Trials (CENTRAL) on the Cochrane Li-
brary, PubMed (from 1966), EMBASE (from 1980). A
highly sensitive RCT filter will be used with the PubMedsearch, as recommended by the Cochrane Handbook
(‘randomized controlled trial’ OR ‘randomized’ OR ‘clinical
trials as topic’ OR ‘placebo’ OR ‘randomly’ OR ‘trial’) NOT
(‘animals’) [22]. We will also conduct searches in Clinical-
trials.gov (http://clinicaltrials.gov/) and the World Health
Organization International Clinical Trials Registry Plat-
form to look for ongoing trials. A comprehensive search
strategy will be performed for unpublished data (contact
with manufactures, FDA website, and request of study
reports).
We will search for articles of original research by using
the following search terms (Additional file 1). Moreover,
the reference lists from the retrieved articles; systematic
reviews and meta-analyses will be checked to search for
further relevant studies. There will be no restrictions on
language or publication year.
Study selection process
Two reviewers will independently screen titles and ab-
stracts of all the retrieved bibliographic records. Full
texts of all potentially eligible records passing the title
and abstract screening level will be retrieved and exam-
ined independently by two reviewers (for each data-
base) with the above mentioned eligibility criteria/
exclusion criteria [23,24]. Disagreements will be re-
solved by consensus or adjudication of another re-
viewer. A flow diagram will outline the study selection
process and reasons for exclusions (full-text).
Data extraction
After determination of the study selection, the following
eligibility criteria will be extracted: first author’s last
name, publication year, country of origin, study design,
study duration, follow-up, study population, number of
arms, participants’ sex and age, sample size, dietary sup-
plement, dose (g/day), mode of administration, baseline
risks (smoking, BMI, hypercholesterolemia, glycemia,
blood pressure, co-medications), indication, specification
of the control group, number of events (all-cause mor-
tality, cardiovascular mortality, cancer mortality, cardio-
vascular incidence, cancer incidence) and hazard ratios,
where reported, withdrawals and drop-outs, adverse
events, and funding source. These variables will be ex-
tracted for all studies, after which the extracted data will
be verified by a second reviewer to reduce reviewer er-
rors and bias.
Risk of bias assessment
Full copies of the studies will be independently assessed
by two authors for methodological quality using the risk
of bias assessment tool from the Cochrane Collaboration
[22,25]. The following sources of bias will be detected:
selection bias (random sequence generation and alloca-
tion concealment), detection bias (blinding of outcome
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formance bias), attrition bias (incomplete outcome data),
reporting bias (selective reporting), and industry bias.
Quality of the evidence
The quality of the evidence will be rated according to
the GRADE guidelines [26,27].
Dealing with missing data
We will try to obtain relevant missing data from authors
of the included trials (by mail).
Statistical analysis
For each outcome measure of interest, pairwise and net-
work random effects meta-analyses will be performed in
order to determine the pooled relative effect of each
intervention relative to every other intervention in terms
of the hazard ratio of the intervention vs. control/pla-
cebo groups. In pairwise meta-analyses, heterogeneity
between trial results will be tested with a Cochran’s Q
test with a value for I2 of >50% considered to represent
substantial heterogeneity [28]. Forest plots will be gener-
ated to illustrate the study-specific effect sizes along with
a 95% CI. To determine the presence of publication bias,
the symmetry of the funnel plots in which mean hazard
ratios will be plotted against their corresponding stand-
ard errors for each comparison where the number of in-
cluded trials is 10 or more. Additionally, Begg’s and
Egger’s regression tests will be performed to detect small
study effects [29,30]. Separate pairwise meta-analyses
will be used to compare all the interventions first.
Network meta-analysis will then be used to synthesize
all the available evidence [31]. Network meta-analysis
methods are extensions of the standard pairwise meta-
analysis model that enable a simultaneous comparison
of multiple interventions while preserving the internal
randomization of individual trials. They have the ad-
vantage of adequately accounting for the correlation
in relative effect estimates from multi-arm trials (trial
with more than two arms) as well as providing a single
coherent summary of all the evidence. Random effects
network meta-analysis models will be used when sub-
stantial heterogeneity is found in any of the pairwise
comparisons for that outcome. Otherwise, the choice
between fixed and random effects will be made by
comparing the deviance information criteria for each
model [31,32]. The model with the lowest deviance in-
formation criterion will be preferred (differences >3
are considered meaningful). Pooled effect sizes from
the network meta-analyses will be presented as poster-
ior medians and 95% credible intervals (that is, the
Bayesian equivalent of CIs) in the appropriate units,
along with the estimated between-study heterogeneity
and its 95% credible interval.Placebo and no treatment will be considered as separ-
ate interventions. For supplements, different modalities
of intake (liquid, pill, and so on) will also be considered
separately. However, if the number of trials comparing
different intake modalities is small, we will explore
models that combine different modalities of intake of a
supplement as a single treatment and will consider pla-
cebo and no treatment as equivalent. Such models will
be acceptable if they are a good fit to the data and have
small between-study heterogeneity. We do not expect
there to be differences in non-active interventions (pla-
cebos) according to their intake modality. However, this
will be explored in the NMA if there are enough data
and we find substantial heterogeneity or inconsistency.
As trial follow-up times are expected to differ and
more events are expected for longer follow-up times, all
meta-analyses (pairwise and network) will be conducted
on the log-hazard ratio scale. Hazard rates will be esti-
mated taking into account trial follow-up for event data
and incorporating hazard ratio data, when these are re-
ported, using a shared parameter model [31,33]. Data
from studies reporting the number of events at a given
follow-up time will be modeled using complementary
log-log regression, and hazard ratios with their uncer-
tainty will be combined in the same NMA using a
‘shared parameter model’ [31,33]. Where studies report
both the number of events and follow-up time and haz-
ard ratios (with a measure of uncertainty), the latter will
be preferred as this accounts for censoring.
For pairwise meta-analyses, data will be analyzed using
Review Manager 5.1 software, provided by the Cochrane
Collaboration (http://ims.Cochrane.org/revman) using
the generic inverse variance method. Network meta-
analyses will be conducted using Markov chain Monte
Carlo simulation implemented with the open-source
software WinBUGS, version 1.4.3 [34]. The WinBUGS
code used is freely available online [31,33].
Minimally informative normal priors will be used for all
treatment effect variables. Uniform priors will be used for
the between-study standard deviation (heterogeneity).
Three Markov chain Monte Carlo chains will be used
to assess convergence using Brooks-Gelman-Rubin plots
and inspection of the trace plots [35]. Posterior summar-
ies will then be obtained from further iterations in each
of the three chains, with a sufficient number of iterations
so that the resulting Monte Carlo error is small.
The potential for inconsistency will be assessed by in-
spection of the available evidence. In case of possible
inconsistency, Bayesian P values for the difference be-
tween direct and indirect evidence will be calculated
using the node-split method, and direct and indirect
estimates will be compared [36,37].
We plan to perform sensitivity analyses for long-term
intervention trials (≥5 years), low risk of bias trials and
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Furthermore, it is planned (if the number of trials is high
enough) to perform sensitivity analysis with respect to
ethnicity and geographical region. The results of the cor-
responding fixed effects models will be also compared in
sensitivity analyses.
Discussion
This systematic review and network meta-analysis will
be the first to pool and compare the effects of different
dietary supplements on all-cause mortality, cardiovascu-
lar and cancer mortality, and incidence, using both dir-
ect and indirect evidence. Since dietary supplements are
often used by populations in the Western world, it is im-
portant to detect the potential benefits and/or harms on
hard clinical outcome parameters. Furthermore, this
analysis will show which dietary supplements, if any, are
the most efficacious in the prevention of the hard clinical
outcome parameters or cause the greatest harm. Results
and conclusions are pending completions of this study.
Our network meta-analysis will be of utility to consumers
of dietary supplements, healthcare providers, and policy-
makers, regarding the use of dietary supplements.
Additional file
Additional file 1: PubMed search strategy.
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